Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell‐derived anti–glypican‐3 chimeric antigen receptor‐expressing natural killer/innate lymphoid cells

• Published in: Cancer science Vol. 111; no. 5; pp. 1478 - 1490
• Main Authors: Ueda, Tatsuki, Kumagai, Ayako, Iriguchi, Shoichi, Yasui, Yutaka, Miyasaka, Tadayo, Nakagoshi, Kengo, Nakane, Kazuki, Saito, Keigo, Takahashi, Mari, Sasaki, Aki, Yoshida, Shinsuke, Takasu, Naoko, Seno, Hiroshi, Uemura, Yasushi, Tamada, Koji, Nakatsura, Tetsuya, Kaneko, Shin
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.05.2020; John Wiley and Sons Inc
• Subjects: Antibodies; Antigens; Cancer immunotherapy; Cancer therapies; CD45 antigen; CD7 antigen; Cell differentiation; chimeric antigen receptor; Chimeric antigen receptors; Clinical trials; Cytotoxicity; GPC3; Heparan sulfate proteoglycans; Histocompatibility antigen HLA; ILC; Immunodeficiency; Immunotherapy; Interferon; iPSC; Liver cancer; Lymphatic system; Lymphocytes; Lymphoid cells; Manufacturers; Natural killer cells; Original; Ovarian cancer; Ovaries; Pluripotency; Quality control; Safety; Stem cell transplantation; Stem cells; Tumor cells; Tumorigenicity; Tumors; Japan; GPC3; ILC; chimeric antigen receptor; NK; iPSC; immunotherapy

The use of allogeneic, pluripotent stem‐cell‐derived immune cells for cancer immunotherapy has been the subject of recent clinical trials. In Japan, investigator‐initiated clinical trials will soon begin for ovarian cancer treatment using human leukocyte antigen (HLA)‐homozygous‐induced pluripotent...